Avricore Health Inc. Files November 2024 6-K Report
Ticker: AVCRF · Form: 6-K · Filed: Dec 5, 2024 · CIK: 1355736
| Field | Detail |
|---|---|
| Company | Avricore Health INC. (AVCRF) |
| Form Type | 6-K |
| Filed Date | Dec 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer, company-update
TL;DR
AVRICORE HEALTH (AVRX) filed its November 6-K, standard foreign issuer report. No major news.
AI Summary
Avricore Health Inc. filed a Form 6-K for the month of November 2024, reporting as a foreign private issuer. The company, formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmaceuticals Inc., and ALDA Pharmaceuticals Corp., is headquartered at 1120-789 West Pender St, Vancouver, BC, V6C 1H2. This filing is made under the Securities Exchange Act of 1934.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Avricore Health Inc.'s status as a foreign private issuer. It confirms their ongoing reporting obligations and company details.
Risk Assessment
Risk Level: low — This filing is a routine report for a foreign private issuer and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- Avricore Health Inc. (company) — Registrant
- Vanc Pharmaceuticals Inc. (company) — Former company name
- NUVA Pharmaceuticals Inc. (company) — Former company name
- ALDA Pharmaceuticals Corp. (company) — Former company name
- 20241130 (date) — Conformed period of report
- 20241205 (date) — Filing date
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of November 2024.
What is Avricore Health Inc.'s principal executive office address?
The principal executive office is located at 1120-789 West Pender St, Vancouver, BC, V6C 1H2.
Has Avricore Health Inc. changed its name previously?
Yes, the company was formerly known as Vanc Pharmaceuticals Inc. (name change date 20140911), NUVA Pharmaceuticals Inc. (name change date 20140110), and ALDA Pharmaceuticals Corp. (name change date 20060309).
Under which SEC Act is this filing made?
This filing is made under the Securities Exchange Act of 1934.
What is the SIC code for Avricore Health Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 410 words · 2 min read · ~1 pages · Grade level 18.8 · Accepted 2024-12-05 17:26:31
Filing Documents
- form6-k.htm (6-K) — 26KB
- ex1.htm (EX-1) — 18KB
- ex2.htm (EX-2) — 46KB
- ex3.htm (EX-3) — 437KB
- ex4.htm (EX-4) — 288KB
- ex5.htm (EX-5) — 14KB
- ex6.htm (EX-10) — 14KB
- ex7.htm (EX-7) — 80KB
- ex1_001.jpg (GRAPHIC) — 8KB
- ex2_001.jpg (GRAPHIC) — 24KB
- ex3_001.jpg (GRAPHIC) — 21KB
- ex4_001.jpg (GRAPHIC) — 21KB
- ex7_001.jpg (GRAPHIC) — 15KB
- 0001493152-24-048913.txt ( ) — 1047KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AVRICORE HEALTH INC. Date: December 05, 2024 By “Kiki Smith” Kiki Smith Chief Financial Officer SEC1815(04-09) Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number